Electrochemical Measurement of Dopamine Release and Uptake in Zebrafish Following Treatment with Carboplatin.
Thomas M FieldMimi ShinChase S StuckyJoseph LoomisMichael A JohnsonPublished in: Chemphyschem : a European journal of chemical physics and physical chemistry (2018)
Post-chemotherapy cognitive impairment, also known as 'chemobrain,' is a neurological condition in which cognitive function is impaired as a result of cancer chemotherapy treatment. In this work, we used fast-scan cyclic voltammetry (FSCV) to measure electrically evoked dopamine release and uptake in whole brain preparations from zebrafish that have been treated with carboplatin, an agent associated with chemobrain. We administered carboplatin by addition to the fish's tank water or their food. One week of treatment with 100 μM carboplatin in the water was needed to significantly impair dopamine release (∼40 % of control); however, only one day of treatment through the zebrafish's food was needed to cause a similar impairment. Atomic absorption spectroscopy measurements suggested that administration through food resulted in higher initial levels of carboplatin compared to water administration, but water administration resulted in an increase over time. Uptake, determined by modeling stimulated release plots, was unaffected. These results are consistent with our previous findings of diminished neurotransmitter release in rats and support a role for zebrafish in chemobrain-related studies.
Keyphrases
- phase ii study
- cognitive impairment
- computed tomography
- magnetic resonance imaging
- magnetic resonance
- young adults
- uric acid
- combination therapy
- high resolution
- metabolic syndrome
- risk assessment
- brain injury
- open label
- single molecule
- phase iii
- mass spectrometry
- replacement therapy
- drug induced
- label free
- case control